Roche, immatics ink oncology agreement
December 2013
by  |  Email the author

TUEBINGEN, Germany—A strategic research and development agreement was announced mid-November between Roche and immatics biotechnologies GmbH, under which the companies will focus on the research, clinical development and commercialization of new tumor-associated peptide (TUMAP)-based cancer vaccine candidates and other cancer immunotherapies, primarily in gastric, prostate and non-small cell lung cancers. Roche will be responsible for clinical development and commercialization of all immunotherapies developed by immatics under the deal, while immatics will also be conducting research on Roche’s behalf using its XPRESIDENT technology platform to identify novel, relevant TUMAP candidates for cancer vaccines and immunotherapies. Also, immatics will receive $17 million up front, in addition to committed research funding and royalties on resulting products, and if all milestones are met, the deal could total more than $1 billion.

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.